Impaired Microbial Fiber Metabolism Identified in Celiac Disease, Independent of Diet

A recent study published in Nature Communications reveals a significant insight into celiac disease (CeD): individuals with the condition exhibit reduced fiber-degrading bacteria and lower microbial fiber metabolism in their small intestine. This crucial finding was observed regardless of adherence to a gluten-free diet (GFD).

The study suggests that impaired microbial processing of fiber, rather than diet alone, may be a fundamental contributing factor in celiac disease.

Celiac Disease: A Brief Overview

Celiac disease is an immune-mediated condition characterized by inflammation and damage to the small intestine, triggered by the ingestion of gluten found in wheat, rye, and barley. While a GFD often alleviates symptoms, it can unfortunately result in fiber deficiency.

Approximately 30% of the population carries a genetic predisposition for CeD, often associated with HLA-DQ2 or DQ8 genes and autoantibodies. However, only a small fraction, 2-3% of these individuals, actually develop the disease. The increasing incidence of CeD points to contributing environmental factors, which may include altered gut microbiota or gut infections.

Dietary fiber is essential for gut health, as gut microbes convert it into short-chain fatty acids (SCFAs), such as acetate and propionate. These SCFAs are linked to improved gastrointestinal function, immune regulation, and beneficial microbial growth. Previous research suggests that consuming fiber-rich foods may even reduce the risk of developing celiac autoantibodies. While the GFD is the primary treatment for CeD, it is often low in fiber and can sometimes result in slow mucosal healing.

Study Methodology and Key Findings

The comprehensive research involved both human subjects and experimental mouse models to explore the link between celiac disease and microbial fiber metabolism.

For the human analysis, researchers examined small intestinal microbiota using duodenal aspirates from three distinct groups:

• 16 newly diagnosed CeD patients
• 11 treated CeD patients who had been on a GFD for over two years
• 26 healthy controls

Distinct microbial profiles were observed across these groups.

• Reduced Fiber Metabolism: CeD patients, irrespective of their GFD status or reported fiber intake, showed a decreased predicted abundance and expression of genes encoding fiber-degrading enzymes, such as starch-degrading α-amylase and fructan β-fructosidase. This reduction was primarily attributed to the depletion of Prevotella species, known for their crucial role in fiber degradation.
• Lower SCFA Production: Decreased SCFA production was noted in CeD patients, with observations made in fecal samples. Treated CeD patients exhibited modestly higher SCFA levels compared to untreated patients, suggesting a partial recovery of fiber-degrading function post-treatment.

Experimental Mouse Model Insights

The study further investigated these findings using a mouse model genetically predisposed to gluten sensitivity, providing valuable corroborating evidence.

• Mice on a GFD with added inulin or HylonVII (a resistant starch prebiotic substrate) showed significant changes in beta-diversity, particularly in the HylonVII group.
• Both inulin and HylonVII supplementation led to seronegativity (absence of antibodies) at 12 weeks.
• Inulin also increased microbial saccharolytic activity (fiber metabolism) and appeared to enhance the GFD response through accelerated intestinal healing, as suggested by histological analysis.

• In separate experiments, germ-free mice and mice with complex microbiota (SPF mice) were compared, with SPF mice showing significantly higher SCFA production.
• Inulin supplementation increased SCFA receptor expression in SPF mice.
• Furthermore, colonizing germ-free DQ8 mice with ten Prevotellaceae strains combined with inulin supplementation resulted in elevated small intestinal SCFA levels.

Limitations and Future Directions

This exploratory study had limitations, including a small sample size for the human analysis and the inference of small intestinal SCFA levels rather than direct measurement in human subjects. However, the findings were strongly corroborated by data from the mouse models.

The study provides compelling evidence that impaired microbial fiber metabolism in CeD patients is influenced not solely by low dietary fiber intake but also by a deficit in key fiber-degrading microbes. These results support further clinical investigation into dietary fiber supplementation and the addition of specific microbes to enhance GFD responses in CeD patients.

Prevotellaceae species, noted for their immunomodulatory potential, are highlighted as potential candidates for further research in therapeutic interventions. Future prospective trials are recommended to further examine the relationship between dietary fiber and gut symptoms in celiac disease.